Stockscreener 앱 받기
776.61
0.42%
-5.0593
전일 마감가:
$781.67
열려 있는:
$771.1
하루 거래량:
101.03K
Relative Volume:
0.12
시가총액:
$82.12B
수익:
$14.34B
순이익/손실:
$4.50B
주가수익비율:
18.69
EPS:
41.5626
순현금흐름:
$3.77B
1주 성능:
-1.10%
1개월 성능:
+3.10%
6개월 성능:
+34.70%
1년 성능:
+11.40%
1일 변동 폭
$769.63
$793.16
1주일 범위
$753.79
$793.16
52주 변동 폭
$476.49
$821.11
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
776.74 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
ARGX
Argen X Se Adr
|
757.80 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.11 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
307.99 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Regeneron’s Dupixent Win And Rare Disease Push Reshape Risk Reward Profile - Yahoo Finance
Rafferty Asset Management LLC Sells 6,156 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC - MarketBeat
Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz
Harvest Portfolios Group Inc. Has $60.47 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Handelsbanken Fonder AB Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by American Century Companies Inc. - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to "Buy" at Wall Street Zen - MarketBeat
Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds - Yahoo Finance
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - WebWire
Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq? - Barchart.com
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expa - GuruFocus
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline - TradingView
Sarcopenia Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Oncocross, Biophytis, MyMD Pharmaceuticals, Novartis, Regeneron Pharma, Merck - StreetInsider
Why Dupixent Keeps Regeneron A Top Big Pharma Pick - Seeking Alpha
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - The Manila Times
Mitsubishi UFJ Asset Management Co. Ltd. Has $121.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Erste Asset Management GmbH Sells 4,661 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Banco Santander S.A. - MarketBeat
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Dupixent’s New FDA Approval For Allergic Fungal Rhinosinusitis - simplywall.st
Regeneron Renews Sponsorship of the Regeneron Science Talent Sear - The National Law Review
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
K.J. Harrison & Partners Inc Has $2.46 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Dana Investment Advisors Inc. Buys Shares of 5,313 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children - Pharmaceutical Executive
Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036 - GlobeNewswire Inc.
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by TD Asset Management Inc - MarketBeat
FDA approves Dupixent as first treatment for AFRS - The Pharma Letter
Fox Run Management L.L.C. Acquires Shares of 4,413 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years - The Globe and Mail
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Cooling - Yahoo Finance
Should FDA Approval of Dupixent in AFRS Patients Prompt Action From Regeneron Pharmaceuticals (REGN) Investors? - Yahoo Finance
Is Dupixent’s First AFRS Approval Altering The Investment Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis - WebWire
FDA Approves Regeneron's (REGN) Dupixent for Allergic Fungal Rhi - GuruFocus
Regeneron Pharmaceuticals, Sanofi Secure FDA Approval for Dupixent Sinus Treatment - marketscreener.com
Sanofi, Regeneron's Allergic Fungal Rhinosinusitis Treatment Gets US FDA Clearance - marketscreener.com
Sanofi and Regeneron's Dupixent approved in the U.S. for Allergic Fungal Rhinosinusitis - marketscreener.com
Regeneron Pharmaceuticals gains FDA approval for allergy treatment - Traders Union
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis - The Manila Times
Dupixent cuts sinus surgeries, steroids 92% in fungal allergy - Stock Titan
Is Regeneron Pharmaceuticals Inc Gaining or Losing Market Support? - Benzinga
M. Kulyk & Associates LLC Purchases 10,368 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Periodic Fever Market Analysis: Trends, Demand, Size, and Key - openPR.com
FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Huda Zoghbi Sells 1,638 Shares - MarketBeat
Is Regeneron (REGN) Still Reasonably Priced After Its Multi Year Share Price Run? - simplywall.st
Regeneron Pharmaceuticals (REGN) Stock Analysis: Navigating Growth with a Promising 11.58% Upside - DirectorsTalk Interviews
Regeneron Pharmaceuticals, Inc. $REGN is Mcdonald Capital Investors Inc. CA's 5th Largest Position - MarketBeat
Lansforsakringar Fondforvaltning AB publ Has $21.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Citigroup Inc. Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.25%
0.51%
자본화:
|
볼륨(24시간):